Clinical trials: Rectal Cancer, Radiotherapy
Metastatic Colorectal Cancer
A Clinical Trial of Durvalumab and Tremelimumab, Administered With Radiation Therapy or Ablation in Patients With Colorectal Cancer
The purpose of this study is to test the safety and effectiveness of two investigational drugs (drugs that are not currently approved by the FDA) given in combination with radiation therapy or ablation.
- Trial name
- NCT03122509
- Testing
- durvalumab, tremelimumab, Radiotherapy (RT)
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Rectal Cancer
Chemoradiation or Brachytherapy for Rectal Cancer
This research is being done to compare the effectiveness of high dose endorectal brachytherapy (END-HDR) and the standard treatment option of chemoradiation with Capecitabine in the treatment of cancer of the lowest part of the…
- Trial name
- CORRECT (NCT02017704)
- Testing
- Endo-HDR (if randomized to this arm), capecitabine and IMRT (if randomized to this arm), IMRT (intensity modulated radiation therapy)
- Where
- 4 sites in United States
- Volunteers
- 9 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Rectal Cancer
Impact of Bladder Depletion on Mesorectal Movements During Radiotherapy in Rectal Cancer
This trial is assessing how Bladder filling variations and thus mesorectal movements are less when radiotherapy treatment is received with an empty bladder in rectal cancer
- Trial name
- MESORECT-VV (NCT04323722)
- Testing
- Empty Bladder pCT and CBCTs, Full Bladder pCT and CBCTs
- Where
- 2 sites in France
- Volunteers
- 53 people
- Sponsor
- Institut Cancerologie de l'Ouest
Rectal Cancer
The Stockholm III Trial on Different Preoperative Radiotherapy Regimens in Rectal Cancer
Preoperative radiotherapy (RT) is recommended to many patients with localised rectal cancer, not previously treated with pelvic RT.
- Trial name
- Stockholm III (NCT00904813)
- Testing
- Short-course RT, Long-course RT
- Where
- 18 sites in Sweden
- Volunteers
- 840 people
- Sponsor
- Karolinska Institutet
Rectal Cancer, Colo-rectal Cancer
A Phase 1-2 Trial of Cetuximab in Combination With Oxaliplatin, Capecitabine, and Radiation Therapy Followed by Surgery for Locally-advanced Rectal Cancer
The objectives of this study are to: 1. To assess dose-limiting toxicities (DLTs) of capecitabine +/- oxaliplatin in a combination regimen with capecitabine and radiotherapy (Phase 1) 2.
- Trial name
- NCT00226941
- Testing
- Cetuximab, Oxaliplatin, Capecitabine
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- George Albert Fisher
Colorectal Cancer
Pilot Study of GVAX in Colorectal Cancer Cells
This study is a Pilot clinical trial. Pilot clinical trials test the safety of an investigational combination of drugs. Pilot studies provide information on what effects, both good and bad, the Investigational agent might have on…
- Trial name
- NCT01952730
- Testing
- GVAX
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Massachusetts General Hospital
Prostate Cancer
Stereotactic Ablative Radiotherapy (SABR) for Low Risk Prostate Cancer With Injectable Rectal Spacer
The purpose is to determine if use of rectal spacers are effective at improving protection of rectum from high dose radiation, using rate of rectal ulceration as a surrogate measure of acute effects.
- Trial name
- NCT02353832
- Testing
- Injectable Rectal Spacer (SpaceOAR, Duraseal or equivalent)
- Where
- 2 sites in United States
- Volunteers
- 44 people
- Sponsor
- University of Texas Southwestern Medical Center
Colorectal Cancer
Capecitabine, Oxaliplatin, and Radiation Therapy in Treating Patients Who Are Undergoing Surgery for Stage I Rectal Cancer
RATIONALE: Drugs used in chemotherapy, such as capecitabine and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00114231
- Testing
- capecitabine, oxaliplatin, neoadjuvant therapy
- Where
- 67 sites in United States
- Volunteers
- 90 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Colorectal Cancer, Colorectal Neoplasms
AMP-224, a PD-1 Inhibitor, With Stereotactic Body Radiation Therapy in Metastatic Colorectal Cancer
Background: T-cells are white blood cells that can find and kill germs and tumors. Cancer can keep T-cells from working. Researchers think a new drug called AMP-224 might help the T-cells in people with cancer.
- Conditions
- Colorectal Cancer, Colorectal Neoplasms, Colorectal Carcinoma
- Trial name
- NCT02298946
- Testing
- AMP-224, Stereotactic Body Radiation Therapy(SBRT), Cyclophosphamide
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- National Cancer Institute (NCI)
Rectal Cancer
BrUOG 302:BYL719, Capecitabine and Radiation for Rectal Cancer: A Brown University Oncology Research Group Study
The primary goal of this Brown University Oncology Research Group is to determine that a safe dose of BYL719 can be administered with capecitabine and radiation in patients with rectal cancer.
- Trial name
- NCT02550743
- Testing
- BYL719, Capecitabine, Radiation
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- howard safran